The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase II MYTHOS trial.
 
Ichiro Kinoshita
Honoraria - Bayer; Chugai Pharma; Guardant Health; Konica Minolta; MSD; Novartis; Pfizer; Takeda
Research Funding - Bayer; Daiich Sankyo; Eisai; Konica Minolta
 
Satoshi Kano
Consulting or Advisory Role - Bayer
Speakers' Bureau - Johnson & Johnson
Research Funding - Daiichi Sankyo
 
Yoshitaka Honma
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; GenMine Labs; Kirin Pharmaceuticals; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis; Rakuten Medical Japan
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; GenMine Labs; Kirin Pharmaceuticals; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Maruho (Inst); Merus (Inst); MSD (Inst); Rakuten Medical Japan (Inst)
 
Naomi Kiyota
Honoraria - Bayer; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Bayer; GlaxoSmithKline; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Kirin Pharmaceuticals (Inst); Ono Pharmaceutical (Inst)
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Naoki Fukuda
Speakers' Bureau - Bayer; Eisai; Lilly; Novartis; Ono Pharmaceutical
Research Funding - Eisai
 
Yoichi Ito
No Relationships to Disclose
 
Yutaka Hatanaka
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly
Speakers' Bureau - AstraZeneca
Research Funding - biomy; BostonGene; Chugai Pharma; CURED; Daiichi Sankyo; Konica Minolta REALM; Lilly; NEC Corporation
 
Yoshihiro Matsuno
No Relationships to Disclose
 
Hirotoshi Akita
Research Funding - Daiichi Sankyo